Portable Blood Monitoring Device Improves Acceptability, Feasibility of Treatment With Clozapine for Schizophrenia

Pin It

A portable device that analyzes blood cell count using a single drop of capillary blood may improve initiation of, and treatment adherence to, clozapine in patients with treatment-resistant schizophrenia, new research suggests.

A small case series study presented here at the American Psychiatric Association (APA) 2010 Annual Meeting illustrates the potential utility of the device in the 20% to 30% of patients with schizophrenia who fail to respond to conventional antipsychotics.

Reported by Caroline Cassels
Medscape Medical News

http://www.medscape.com/viewarticle/722983?sssdmh=dm1.622437&src=confwrap&uac=30831FZ

Submitted by SARDAA

Comments

  1. Linda Fonti says:

    I am curious to find if the FDA has approved the portable blood monitoring device (CHEMPAQ) for use in the states. I work for the office of mental health and first became aware of this device for Clozapine monitoring the Fall od 2011. If you have any information, I would greatly appreciate it.
    Thank You,
    Linda

  2. I can’t find anything that finalizes the FDA approval. Best to contact Jimmi Nielsen, MD. I’m sorry I don’t know more!

Speak Your Mind

*